Timber Pharmaceuticals, Inc.
TMBR
TMBR was delisted on the 28th of November, 2023.
13 hedge funds and large institutions have $595K invested in Timber Pharmaceuticals, Inc. in 2022 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 7 increasing their positions, 1 reducing their positions, and 4 closing their positions.
600% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 1
1.27% less ownership
Funds ownership: 4.24% → 2.97% (-1.3%)
13% less funds holding
Funds holding: 15 → 13 (-2)
43% less capital invested
Capital invested by funds: $1.04M → $595K (-$447K)
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Northern Trust
Chicago,
Illinois
|
+$18K |
| 2 |
Barclays
London,
United Kingdom
|
+$14.6K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$12.1K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$10.4K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$9.81K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$249K |
| 2 |
BlackRock
New York
|
-$34.7K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$19K |
| 4 |
Two Sigma Investments
New York
|
-$17K |
TMBR Hedge Fund Activity: Q2 2022 in Review
13 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Timber Pharmaceuticals, Inc. (TMBR) for Q2 2022, worth a combined $595K — down 43% from $1.04M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of TMBR and 2 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 7 added.
The largest buyer was Northern Trust, adding an estimated $18K. The largest seller was Renaissance Technologies, cutting an estimated $249K.
- 13 institutional investors held Timber Pharmaceuticals, Inc. (TMBR) as of Q2 2022, down from 15 in Q1 2022.
- Funds reported $595K of Timber Pharmaceuticals, Inc. stock for Q2 2022, down 43% quarter-over-quarter.
- 2 funds opened new Timber Pharmaceuticals, Inc. positions in Q2 2022 and 4 closed out, a net change of -2 holders.
- The largest Timber Pharmaceuticals, Inc. buyer in Q2 2022 was Northern Trust, an estimated $18K added.
- The largest Timber Pharmaceuticals, Inc. seller in Q2 2022 was Renaissance Technologies, an estimated $249K sold.
Based on aggregated 13F filings for Q2 2022.